| Methods |
4‐ to 6‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 92‐109 mm Hg on last 2 visits of run‐in; 4‐week double‐blind treatment at fixed dose, after 4‐weeks captopril dosage doubled in all randomized patients for additional 4 weeks |
| Participants |
Captopril 50 mg once daily: n=88(58 males,30 females); mean age=52 years; baseline sitting SBP=149.3 mm Hg, DBP=98.2 mm Hg;
Captopril 50 mg twice daily: n=91(60 males,31 females); mean age=52 years; baseline sitting SBP=151.2 mm Hg, DBP=100.1 mm Hg;
Placebo: n=90(58 males,32 females); mean age=51 years; baseline sitting SBP=148.7 mm Hg, DBP=98.5 mm Hg |
| Interventions |
Captopril 50 mg once daily;
Captopril 50 mg twice daily;
Placebo;
patients in daily schedule groups received their active medication in the morning and placebo in the evening |
| Outcomes |
Sitting DBP |
| Notes |
Used week 4 BP data only; BP change not reported, SD of change not reported, endpoint SBP not reported; endpoint DBP reported; endpoint SD not reported; baseline SD not reported; imputed overall trial mean SD of change for DBP; DBP data from Table 3, p. 382; BP measurement device not reported; Jadad score=2; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
